Core Insights - Zai Lab is conducting a 2025 Triple Meeting Investor Call to discuss its global asset portfolio and clinical data updates [1][2] - The agenda includes an overview of the global asset portfolio, detailed presentation of updated clinical data for Zoci, and future steps for the program [3] Company Overview - Zai Lab focuses on oncology and immunology as its two core areas for global development [4] - The company is highlighting its growing global innovation pipeline, particularly emphasizing Zoci as a potential first and best-in-class DLL3 targeted therapy [4]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Summary of Zai Lab's Conference Call Company Overview - **Company**: Zai Lab - **Focus Areas**: Oncology and Immunology - **Key Product**: Zosi, a DLL3-targeted antibody-drug conjugate (ADC) Key Points on Zosi Development - **Clinical Trials**: - Initiated a global phase three trial for Zosi in second-line small cell lung cancer (SCLC) and expanding into first-line SCLC and neuroendocrine carcinomas (NECs) [2][5][18] - Zosi has shown a 68% overall response rate (ORR) in second-line patients at a dose of 1.6 mg/kg and an 80% ORR in patients with untreated brain metastases [4][14] - The median duration of response is 6.1 months across all doses [15] - **Safety Profile**: - Zosi demonstrated a low rate of grade three treatment-related adverse events at 13%, significantly lower than other ADCs [12] - No treatment discontinuations due to toxicity were reported [16] - **Patient Population**: - The trial includes heavily pretreated patients, with over 90% having received prior anti-PD-L1 or PD-1 therapy [11] - Approximately one-third of patients had brain metastases, which is significant given the poor prognosis associated with this condition [11][52] Market Context and Competitive Landscape - **Urgent Need for New Therapies**: - SCLC accounts for about 15% of lung cancer cases, with over 370,000 new cases annually worldwide [6] - Current treatment options are limited and often associated with high toxicity and poor long-term outcomes [7][8] - **Positioning Against Competitors**: - Zosi is positioned as a chemotherapy-sparing option, which could enhance its appeal in the first-line treatment setting [26][34] - The competitive landscape includes Imdeltra, which is expected to become a front-line agent, but Zosi's rapid onset of action and favorable safety profile may provide a competitive edge [25][34] Future Development Plans - **Upcoming Trials**: - A randomized phase two study is ongoing to optimize dose selection, with plans for a pivotal study in the front-line setting in 2026 [19][48] - Zai Lab is also exploring combination strategies with other agents to enhance Zosi's efficacy [58] - **Regulatory Strategy**: - Zai Lab aims for accelerated approval based on response and durability of response, with a potential filing in 2027 [23][41] - The FDA has agreed on the focus doses of 1.2 and 1.6 mg/kg for the pivotal trial [45] Additional Insights - **Brain Metastasis Efficacy**: - Zosi has shown promising results in patients with brain metastases, with an 80% response rate, highlighting its potential for treating this challenging aspect of SCLC [52][54] - **Long-term Vision**: - Zai Lab is committed to reshaping the treatment paradigm for SCLC and NECs, with a focus on delivering innovative therapies that improve patient outcomes [19][60] Conclusion - Zai Lab is advancing Zosi as a potential best-in-class treatment for SCLC, with a strong emphasis on safety, efficacy, and rapid development timelines. The company is well-positioned to address significant unmet needs in oncology, particularly in challenging patient populations.

Core Points - The Hong Kong Innovative Drug ETF (159567) closed down 0.12% with a trading volume of 797 million yuan on October 24, 2024 [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of October 23, 2024, the fund's latest share count was 8.225 billion shares, with a total size of 6.801 billion yuan, reflecting a year-to-date increase of 1980.29% in shares and 1700.12% in size [1] Fund Performance - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 65.38% during the tenure [2] - The fund's performance benchmark is the National Index for Hong Kong Innovative Drugs, adjusted for valuation exchange rates [1] Liquidity and Trading Activity - Over the last 20 trading days, the ETF has accumulated a trading amount of 22.849 billion yuan, with an average daily trading amount of 1.142 billion yuan [1] - Since the beginning of the year, the ETF has recorded a total trading amount of 227.996 billion yuan over 195 trading days, averaging 1.169 billion yuan per day [1] Top Holdings - The ETF's top holdings include: - Innovent Biologics (9.52% holding, 26 million yuan market value) - WuXi Biologics (9.47% holding, 25.8 million yuan market value) - BeiGene (8.73% holding, 23.8 million yuan market value) - CanSino Biologics (7.62% holding, 20.8 million yuan market value) - China National Pharmaceutical Group (7.17% holding, 19.6 million yuan market value) [2]

Core Viewpoint - CATL (Contemporary Amperex Technology Co., Limited) has demonstrated significant financial growth in Q3 2025, achieving record profits and revenue, while also expanding its market presence internationally and diversifying its business model towards energy storage and consumer markets [4][6][14]. Financial Performance - In Q3 2025, CATL reported revenue of 1041.86 billion yuan, a year-on-year increase of 12.90%, and a net profit of 185.49 billion yuan, up 41.21%, marking the highest quarterly profit in the company's history [4][11]. - For the first three quarters of 2025, total revenue reached 2830.72 billion yuan, with a year-on-year growth of 9.28%, and net profit increased by 36.20% to 490.34 billion yuan [5][6]. - The company's operating cash flow for the first three quarters was 806.6 billion yuan, reflecting a 19.6% increase, indicating strong self-financing capabilities [7][11]. Profitability and Margins - CATL's net profit margin in Q3 reached 19.1%, an increase of 4.1 percentage points compared to the same period last year, highlighting improved profitability [15]. - The company achieved an average daily profit of over 200 million yuan in Q3, compared to less than 140 million yuan in the previous year [13]. Market Position and Challenges - Despite maintaining a leading position in the global electric vehicle battery market with a 36.8% share, CATL's market share has slightly declined from 37.7% year-on-year [24]. - In the domestic market, CATL's share decreased by 3.1 percentage points to 42.75%, marking the lowest level in five years [24]. International Expansion and Strategy - CATL's overseas revenue reached 612 billion yuan in the first half of 2025, accounting for 34.22% of total revenue, with plans to increase overseas production capacity to 40% by 2026 [27]. - The company is focusing on expanding its presence in Europe and North America, with significant market shares of 35% and 28% respectively [28]. - The funds raised from the Hong Kong IPO are primarily allocated for overseas capacity construction, particularly in Hungary [27][29]. Diversification into Energy Storage - CATL is increasing its focus on energy storage systems, which accounted for approximately 20% of its total shipments in Q3 2025 [31]. - The company is expanding its production capacity for energy storage batteries across multiple locations in China, anticipating significant demand from data centers [31]. New Business Ventures - CATL is entering the consumer market with its battery swapping service, targeting the C-end market for the first time, which could open new growth avenues [33][34].

Core Viewpoint - The company, Zai Lab (09688.HK), announced that its board's audit committee will review and approve the unaudited quarterly performance for the third quarter ending September 30, 2025, on November 6, 2025, in accordance with US GAAP and SEC regulations [1] Group 1 - The board's audit committee is scheduled to meet on November 6, 2025 [1] - The meeting will focus on the unaudited quarterly results for the three and nine months ending September 30, 2025 [1] - The results will be prepared in compliance with US GAAP and applicable SEC rules [1]

Zai Lab Limited 再鼎醫藥有限公司 * （於開曼群島註冊成立的有限公司） （股份代號：9688） 審核委員會行動通告及 2025 年第三季度業績公告的發佈日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不會對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任何損失承擔任何責任。 在第三季度業績獲批准及發佈後，本公司管理層計劃在 2025 年 11 月 6 日（星期四，美國東部時間） 上午 8:00/2025 年 11 月 6 日（星期四，香港時間）下午 9:00 舉行現場業績電話會議及網絡直播，以討 論第三季度業績並回答提問。有意參會人士可透過本公司網站 http://ir.zailaboratory.com 參與網絡直播。 所有參與者均須於電話會議前透過下文提供的連結完成線上登記流程。登記後，參與者將收到提供撥 號詳情的確認郵件。 網絡直播登記連結： https://edge.media-server.com/mmc/p/svanah67 拨入登記連結：https://register-conf.med ...

- 1 - (A) 人數。委員會應由至少三名成員組成。 (B) 獨立性。委員會的每名成員均應符合納斯達克全球市場（「納斯達克」）及香 港聯合交易所有限公司證券上市規則（「香港上市規則」）的適用獨立性 要求，並符合「獨立董事」的資格。 (C) 主席。除非主席由董事會委任，否則委員會成員應通過委員會全體成員的 多數票指定一名主席。主席應領導委員會，包括制定會議議程、主持會議、 分配小組委員會任務及代表委員會向董事會報告。 (D) 關於成員資格的決定。委員會的成員應由董事會委任並可由董事會酌情罷 免。董事會將至少每年評估是否符合上述成員資格要求。 再鼎醫藥有限公司董事會 提名及企業管治委員會章程 （於2025年10月22日獲董事會採納） I. 宗旨和權限。 再鼎醫藥有限公司（「公司」）董事會（「董事會」）下設的提名及企業管治委員會（「委 員會」）的宗旨是履行董事會授予有關企業管治及董事提名的職責。 II. 組成。 III. 程序和管理。 (A) 董事會和委員會事務；企業管治。 (1) 董事提名人選。委員會應按董事會批准的標準物色有資格成為董事會成 員的人士，接收並審查有關合格人士的提名及審查首席執行官提出的推 薦； ...

Core Viewpoint - The Hong Kong stock market's innovative drug sector is experiencing a decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 3.5% as of the report, indicating a potential buying opportunity for investors despite the downturn [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a trading volume exceeding 200 million yuan, continuing to exhibit high premiums in the market [1] - The innovative drug sector faced a significant drop recently, with the ETF attracting over 75 million yuan in a single day, totaling over 120 million yuan in the last four days [1] Group 2: Recent Developments - The ESMO 2025 conference recently showcased positive data for several core projects of Chinese innovative drugs [1] - On October 22, Innovent Biologics announced a global strategic partnership with Takeda Pharmaceutical worth 11.4 billion USD, setting a record for the value of business development (BD) transactions in China's innovative drug sector, involving three product rights and pipeline development [1] Group 3: Future Outlook - Huafu Securities suggests that the recent adjustments in the Hong Kong innovative drug sector may present a significant opportunity for investment in late October [1] - The long-term outlook remains positive for companies with commercialization capabilities and rich pipelines, particularly in BioPharma, potential BD targets, and cutting-edge technology [1] - The innovative drug industry is expected to benefit from interest rate cuts, with performance anticipated to improve, and the end-of-year BD period may act as a catalyst for growth [1] Group 4: Index Composition - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its linked fund (025220) passively track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which includes top ten weighted stocks such as BeiGene, China Biologic Products, Innovent Biologics, and others [1]

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 0.46% on October 20, with a trading volume of 907 million yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 17, 2024, the fund's shares totaled 8.134 billion, with a total size of 6.968 billion yuan, reflecting a significant increase in both shares and size compared to the previous year [1] Fund Performance - The fund has seen a remarkable increase of 1957.27% in shares and 1744.35% in size since December 31, 2023 [1] - The fund's cumulative trading amount over the last 20 trading days reached 27.487 billion yuan, with an average daily trading amount of 1.374 billion yuan [1] - Year-to-date, the cumulative trading amount is 224.063 billion yuan, averaging 1.173 billion yuan per day over 191 trading days [1] Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 71.34% during the management period [2] - The fund's top holdings include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant percentages of the portfolio allocated to these stocks [2]